Alimera Resubmits Iluvien In U.S. As It Begins EU Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.